Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
3期
进行中（已停止招募）
NCT03043872
| 适应症 | Small Cell Lung Carcinoma Extensive Disease |
|---|
| 分期 | 3期 |
|---|
| 申办方 | AstraZeneca |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 987 人 |
|---|
| 干预（药物） | Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide |
|---|
| 开始日期 | 2017年3月27日 |
|---|
| 完成日期 | 2020年1月27日 |
|---|
| 结果公布日 | 2021年3月4日 |
|---|
摘要
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer
Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP
From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months). · months
| Global Cohort: D + EP | 13.0 months |
|---|
| Global Cohort: EP | 10.3 months |
|---|
| p-value | 0.0047 |
|---|
| Hazard Ratio (HR) | 0.73 (95% CI 0.591–0.909) |
|---|
OS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP
From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months). · months
| Global Cohort: D + T + EP | 10.4 months |
|---|
| Global Cohort: D + EP | 12.9 months |
|---|
| Global Cohort: EP | 10.5 months |
|---|
| p-value | 0.0032 |
|---|
| Hazard Ratio (HR) | 0.75 (95% CI 0.625–0.910) |
|---|
OS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP
From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months). · months
| China Cohort: D + EP | 14.4 months |
|---|
| China Cohort: EP | 10.9 months |
|---|
| p-value | 0.0664 |
|---|
| Hazard Ratio (HR) | 0.65 (95% CI 0.414–1.029) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。